FY2025 Earnings Forecast for NBIX Issued By William Blair

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Stock analysts at William Blair cut their FY2025 earnings per share estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the company will earn $3.71 per share for the year, down from their previous estimate of $3.87. William Blair has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

A number of other analysts have also recently issued reports on NBIX. Needham & Company LLC increased their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Canaccord Genuity Group increased their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. BMO Capital Markets increased their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They set a "hold" rating and a $138.00 price objective on the stock. Finally, UBS Group raised their price target on Neurocrine Biosciences from $137.00 to $152.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $162.00.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded down $2.32 during trading on Thursday, reaching $118.11. 622,444 shares of the stock traded hands, compared to its average volume of 1,116,013. The company has a 50-day moving average of $106.36 and a 200-day moving average of $121.93. The stock has a market capitalization of $11.69 billion, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. During the same quarter last year, the company earned $1.20 EPS. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year.

Neurocrine Biosciences declared that its Board of Directors has initiated a share buyback plan on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director William H. Rastetter sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at $4,131,508.20. This trade represents a 44.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matt Abernethy sold 2,558 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.86, for a total value of $298,927.88. Following the completion of the transaction, the chief financial officer now owns 34,775 shares of the company's stock, valued at approximately $4,063,806.50. The trade was a 6.85% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,953 shares of company stock worth $4,467,990. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Golden State Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $25,000. Huntington National Bank lifted its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the period. Brooklyn Investment Group lifted its stake in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the period. GeoWealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the period. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Neurocrine Biosciences during the first quarter valued at $34,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.